Abstract Details

Title Patient Characteristics and Frequency of Exacerbations in Incident Myasthenia Gravis: Analysis of US Commercial Insurance Claims Data

Topic Global Health and Neuroepidemiology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 075

Objective

To estimate the incidence of myasthenia gravis (MG) in the United States (US), and to assess the frequency of and time to exacerbations among patients with MG.

Background

The incident MG population in the US is not well-characterized. Many patients experience exacerbations despite the use of conventional immunosuppressive treatments; however, this has not been studied in detail.

Design/Methods

This retrospective analysis used Inovalon claims data to estimate the incidence of MG among adults aged ≥18 years in the US for 2019. Patient characteristics, treatment utilization patterns, and exacerbation frequency were assessed in the incident population.

Results We identified 1,372 incident patients with MG, corresponding to a raw incidence rate of 4.9 per 100,000 persons, and an adjusted incidence of 5.2 per 100,000 after extrapolating to the US population. More than half (56.9%) of the patients were women, and the median age for women (58 years) was lower than the age for men (62 years). Hypertension was the most common comorbidity, occurring in 50.4% of patients. Among 920 patients who received medication, 773 (84.0%) were treated with acetylcholinesterase inhibitors. Among 1,204 incident patients with ≥1 year of continuous follow-up, 387 (32.1%) experienced exacerbations, with the majority experiencing ≥3 exacerbations. Median (interquartile range [IQR]) time to first exacerbation was 7 (60) days, and in patients with >1 exacerbation, the median (IQR) time from the first to subsequent exacerbation was 25 (42) days.

Conclusions

The estimated incidence of MG among adults in the US was 5.2 per 100,000 persons. Approximately one-third of patients experienced exacerbations within a year, with >50% of those patients having ≥3 exacerbations. These findings highlight the unmet need for targeted therapies that provide sustained symptom control.

Authors/Disclosures
Lesley-Ann 9. Miller-Wilson, PhD (Immunovant) PRESENTER	Dr. Miller-Wilson has received personal compensation for serving as an employee of Immunovant Inc. Dr. Miller-Wilson has or had stock in Immunovant Inc..
Paola Mina-Osorio, MD, PhD (Immunovant)	Dr. Mina-Osorio has received personal compensation for serving as an employee of Immunovant. Dr. Mina-Osorio has stock in Immunovant, Inc..
Joel Arackal (University of Health Sciences and Pharmacy)	No disclosure on file
Jingyu Wang	No disclosure on file
Jennifer Schwinn	Jennifer Schwinn has received personal compensation for serving as an employee of Immunovant, Inc..
Brett Venker (Roivant Sciences)	No disclosure on file

��ɫ��

��ɫ��